IMCR · Immunocore Holdings plc
Market Cap
$1.58B
Shares
51.50M
Volume · Oct 5
329.45K
Avg daily vol (3M)
454.83K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$29.59
Open$29.98
Day$29.39–30.48
52W close$27.79–40.22
Avg vol 30d387K
Short int7.8M · 15.1% float · 20.6d
Short vol21%
Last earningsAug 6, 2026
DataFeb 2021–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Feb 4, 2027
Est · unconfirmed
· in 17 wks
filed Aug 6, 2026
call held Feb 25, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$430.77M
Trailing 12 months
Net income (TTM)
−$18.07M
Trailing 12 months
Revenue growth YoY
+18.3%
Year over year
Operating margin
-5.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.4%
Year over year · more shares
Price change (1Y)
-15.8%
Trailing year
Short interest
15.1%
Latest settlement · 20.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−8%
below
Price vs 50-day avg
−13%
below
RSI (14)
28
oversold
MACD trend
Negative
52-week position
14%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−18%
trailing
6-month return
−7%
trailing
YTD return
−15%
this year
Relative strength
−18%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $34 › 200d $32 — 50d above 200d
Institutional flow
Distributing
-6% holders QoQ · +25 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.09% of float · ▼ -0.3% MoM · 20.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
135 holders — mid 3-yr range
Squeeze score
76
high risk · 0–100
Fundamentals
Revenue growth
+43%
Y/Y
EPS growth
+30%
Y/Y
Free cash flow
$-15.1M
Quant / Vol
risk profile
Volatility
37%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
4.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−8%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
28
Neutral
MACD trend
Negative
Bearish
52-week position
14%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $34 › 200d $32 — 50d above 200d
Institutional flow
Distributing
-6% holders QoQ · +25 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.09% of float · ▼ -0.3% MoM · 20.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
135 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $28
Now $30 · 14%
Range high $40
vs 200-day avg -8%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Control arm five-year overall survival rate | 8% | five years | — |
| KIMMTRAK five-year overall survival rate | 16% | five years | — |
| KIMMTRAK net product sales growth | 16% | the six months ended June 30, 2026 | — |
| Mean duration of treatment | 14 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMCR
this stock
Immunocore Holdings plc
|
$1.58B | -14.8% | +43.1% | — | 15.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMCR | -3.4% | -18.1% | -6.6% | -2.3% | -14.8% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -4.6% | -18.7% | -18.2% | -3.9% | -28.4% |